Compound Screening TRIZ Cases

Reduced sodium culture medium prevents cytotoxicity while molecular beacons enable high-throughput screening of epithelial sodium channel modulators.

Engineered IL-1F8 polypeptides resolve unclear processing mechanisms by optimizing N-terminal sequences to antagonize or agonize IL-1Rrp2 signaling.

A Gal3:TIM-3 inhibitor interferes with galectin-3 and TIM-3 protein binding to activate T-cells.

Engineered ligand-binding domains stabilize upon small molecule binding to enable modular in vivo detection via reporter gene expression.

Optimized BSK-H medium with rabbit serum and reducing agents supports stable spirochete growth.

Light-activated ion channel polypeptides alter membrane potential using blue and green light to depolarize excitable cells.

Screening compounds that block ASK1 N-terminal dimerization mitigates steatohepatitis pathology in animal models.

Segmentation of fusion subtypes via molecular diagnostics improves therapeutic targeting precision for cancer cells expressing FGFR2-VCL.

Wearable sensors track physiological data to identify toxicity indications, reducing hospitalization duration and healthcare costs.

Non-woven fabric scaffold grows 3D tissueoids to resolve low physiological relevance in traditional 2D cell culture models.

Inactive enzymes in a separation gel reactivate to identify kinase substrates, mapping the substrate spectrum before inhibitor development.

Phenylcyclopropylamine derivatives inhibit LSD1 and monoamine oxidase B enzymes through competitive binding mechanisms.

Replacing labor-intensive Western blotting with automated fluorescence detection, this assay resolves low throughput and non-quantitative limitations.

Three-dimensional pancreatic organoids replicate in vivo tissue architecture for precise biological analysis.

Targeting the lysine-CoA inhibitor binding site resolves low specificity in p300/CBP modulation, enabling potent therapeutic agents for cancer and diabetes.

Peroxiredoxin 2 eliminates hydrogen peroxide to stabilize cellular redox potential, preventing neointimal thickening after coronary angioplasty.

Ex vivo optical signal analysis quantifies cell membrane motion to detect drug-induced damage and predict treatment responses.

Fluorescent assay identifies compounds dissociating hexokinase from mitochondria, resolving the trade-off between screening capacity and assay accuracy.

Using Ifi205 as a molecular target avoids side effects and resistance from traditional analgesics while enabling novel drug discovery.